Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

被引:5
作者
Kagstrom, E. [1 ]
Lannergard, A. [1 ]
El Khosht, J. [2 ]
Lorelius, P. [2 ]
Manflod, J. [2 ]
Stromdahl, S. [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, Infect Dis, Uppsala, Sweden
[2] Reg Uppsala, Needle & Syringe Program Uppsala, Nara Vard Och Halsa, Uppsala, Sweden
关键词
Hepatitis C; People who inject drugs; Needle exchange program; Harm reduction; Injection drug use; Injection risk behavior; Reinfection; Needle syringe program; ACTING ANTIVIRAL AGENTS; GENOTYPE DISTRIBUTION; INFECTION; EPIDEMIOLOGY; TRANSMISSION;
D O I
10.1186/s12954-023-00806-w
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundThe World Health Organization has set a goal to reach world elimination of hepatitis C virus (HCV) by 2030. Needle and syringe programs (NSP) for people who inject drugs (PWID) are crucial to achieve this goal. The NSP in Uppsala, Sweden, was opened in 2016 and has since 2018 provided HCV treatment for PWID. The aim of this study was to investigate HCV prevalence, risk factors and treatment uptake and outcome in NSP participants.MethodsData from 450 PWID registered at the Uppsala NSP between 2016-11-01 and 2021-12-31 were collected from the national quality registry InfCare NSP. Data from the 101 PWID treated for HCV at the Uppsala NSP were collected through patient journal review. Descriptive and inferential analysis was performed. Ethical approval was obtained from the Ethical Review Board in Uppsala (dnr 2019/00215).ResultsThe mean age was 35 years. 75% were males (336/450), and 25% were females (114/450). The overall HCV prevalence was 48% (215/450) with a declining trend over time. Factors associated with a higher risk of HCV were older age at registration (OR 1.025, 95% CI 1.004-1.046), lower age at injection drug debut (OR 0.963, 95% CI 0.932-0.996), lower education level (OR 1.829, 95% CI 1.185-2.821) and higher number of total visits at the NSP (OR 1.005, 95% CI 1.001-1.009). The overall HCV treatment uptake was 47% (101/215), of which 77% (78/101) completed HCV treatment. The HCV treatment compliance was 88% (78/89). 99% (77/78) were cured with a sustained virologic response 12 weeks after completed treatment. The reinfection rate over the study period was 9/77 (11.7%); all were male with mean age of 36.ConclusionsHCV prevalence, treatment uptake and treatment outcome have improved since the opening of the Uppsala NSP. However, further measures are needed to reach the HCV elimination goal. Outreach HCV treatment programs for PWID should be explored and evaluated in combination with further implementation of low-threshold programs.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Mortality and causes of death among people who inject amphetamine: A long-term follow-up cohort study from a needle exchange program in Sweden
    Ahman, Ada
    Jerkeman, Anna
    Blome, Marianne Alanko
    Bjorkman, Per
    Hakansson, Anders
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2018, 188 : 274 - 280
  • [2] Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus
    Aleman, Soo
    Soderholm, Jonas
    Busch, Katharina
    Kovamees, Jan
    Duberg, Ann-Sofi
    [J]. LIVER INTERNATIONAL, 2020, 40 (08) : 1832 - 1840
  • [3] Epidemiology of hepatitis C virus infection
    Alter, Miriam J.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) : 2436 - 2441
  • [4] [Anonymous], 2013, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach
  • [5] Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19
    Blach, Sarah
    Blome, Marianne
    Duberg, Ann-Sofi
    Jerkeman, Anna
    Kaberg, Martin
    Klasa, Per-Erik
    Lagging, Martin
    Razavi-Shearer, Devin
    Razavi, Homie
    Aleman, Soo
    [J]. LIVER INTERNATIONAL, 2021, 41 (09) : 2024 - 2031
  • [6] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
    Blach, Sarah
    Zeuzem, Stefan
    Manns, Michael
    Altraif, Ibrahim
    Duberg, Ann-Sofi
    Muljono, David H.
    Waked, Imam
    Alavian, Seyed M.
    Lee, Mei-Hsuan
    Negro, Francesco
    Abaalkhail, Faisal
    Abdou, Ahmed
    Abdulla, Maheeba
    Abou Rached, Antoine
    Aho, Inka
    Akarca, Ulus
    Al Ghazzawi, Imad
    Al Kaabi, Saad
    Al Lawati, Faryal
    Al Namaani, Khalid
    Al Serkal, Youssif
    Al-Busafi, Said A.
    Al-Dabal, Layla
    Aleman, Soo
    Alghamdi, Abdullah S.
    Aljumah, Abdulrahman A.
    Al-Romaihi, Hamad E.
    Andersson, Monique I.
    Arendt, Vic
    Arkkila, Perttu
    Assiri, Abdullah M.
    Baatarkhuu, Oidov
    Bane, Abate
    Ben-Ari, Ziv
    Bergin, Colm
    Bessone, Fernando
    Bihl, Florian
    Bizri, Abdul R.
    Blachier, Martin
    Blasco, Antonio J.
    Mello, Carlos E. Brandao
    Bruggmann, Philip
    Brunton, Cheryl R.
    Calinas, Filipe
    Chan, Henry L. Y.
    Chaudhry, Asad
    Cheinquer, Hugo
    Chen, Chien-Jen
    Chien, Rong-Nan
    Choi, Moon Seok
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 161 - 176
  • [7] Hepatitis C treatment at a Swedish needle exchange program, a successful model of care - the ACTIONNE study
    Blome, Marianne Alanko
    Braback, Martin
    Alsterberg, Sara
    Jerkeman, Anna
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 96
  • [8] Centralforbundet for alkoholoch narkotikaupplysning [The Swedish Council for Information on Alcohol and Other Drugs, 2019, DROG SVER 2019, P26
  • [9] Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada
    Delaunay, Charlotte Laniece
    Maheu-Giroux, Mathieu
    Marathe, Gayatri
    Saeed, Sahar
    Martel-Laferriere, Valerie
    Cooper, Curtis L.
    Walmsley, Sharon
    Cox, Joseph
    Wong, Alexander
    Klein, Marina B.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 103
  • [10] Viral hepatitis in 2021: The challenges remaining and how we should tackle them
    Dunn, Rebecca
    Wetten, Aaron
    McPherson, Stuart
    Donnelly, Mhairi C.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (01) : 76 - 95